Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene

Xandra García-González^{1,*}
Sara López-Tarruella^{2,*}
María Isabel García¹
Eva González-Haba¹
Carolina Blanco¹
Sara Salvador-Martin¹
Yolanda Jerez²
Fabienne Thomas³
María Jarama¹
María Sanjurjo Sáez¹
Miguel Martín²
Luis Andrés
López-Fernández¹

¹Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; ²Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; ³Department of Pharmacology, Institut Claudius-Regaud, CRCT, Université de Toulouse, Inserm, UPS, Toulouse, France

*These authors contributed equally to this work

Correspondence: Luis Andrés López-Fernández
General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Servicio de Farmacia, Doctor Esquerdo 46, 28007, Madrid, Spain
Tel +34 91 426 5026
Email luis.lopez@iisgm.com

Abstract: Severe, life-threatening adverse reactions to capecitabine sometimes occur in the treatment of solid tumors. Screening for dihydropyrimidine dehydrogenase (DPYD) deficiency is encouraged before start of treatment, but the genetic variants that are commonly analyzed often fail to explain toxicities seen in clinical practice. Here we describe the case of a 79-year-old Caucasian female with breast cancer who presented with life-threatening, rapidly increasing toxicity after 1 week of treatment with capecitabine and for whom routine genetic *DPYD* test resulted negative. *DPYD* exon sequencing found variant c.2242+1G>T at the donor splicing site of exon 19. This variant is responsible for skipping of exon 19 and subsequent generation of a non-functional *DPYD* enzyme. This variant has not been described previously but was found in three other members of the patient's family. With this case, we show that exon sequencing of *DPYD* in patients who experience marked toxicity to fluoropyrimidines and test negative for commonly evaluated variants can prove extremely useful for identifying new genetic variants and better explain adverse reactions causality.

Keywords: pharmacogenetics, adverse drug reaction, fluoropyrimidine, breast cancer

Introduction

Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) that is rapidly and extensively absorbed in the intestine before conversion to 5-FU.¹ Severe, life-threatening, and even fatal toxicity has been associated with deficient dihydropyrimidine dehydrogenase (DPYD) activity in patients receiving fluoropyrimidine-based chemotherapy at standard doses.² Capecitabine-induced adverse reactions include severe hand-foot syndrome, gastrointestinal toxicity, hematological toxicity, and cardiotoxicity.^{3,4}

Low *DPYD* activity is partly explained by genetic variability in the *DPYD* gene, which is highly polymorphic.^{5,6} However, only a few variants (ie, rs3918290 [*DPYD**2A], rs55886062 [*DPYD**13], and rs67376798) have been clearly associated with severe toxicity to fluoropyrimidines. In our hospital, genotyping of these three variants is available on request for patients starting fluoropyrimidine therapy and has proved to be cost-effective.⁷ Nonetheless, this test enables us to avoid only 10%–15% of capecitabine-related severe adverse reactions, thus strongly suggesting that other genetic variants in *DPYD* or in other genes might also be implicated.⁸ *DPYD* phenotyping based on the measurement of the enzyme activity in peripheral blood mononuclear cells is another proposed approach to minimize life-threatening toxicity.⁹ It is yet to be discerned which of these approaches offers the better predictive value and is the most cost-effective to implement or whether a combination of both would be the preferred choice.

Case report

A 79-year-old Caucasian woman was diagnosed with poorly differentiated carcinoma that appeared to have originated in breast tissue. She underwent a second-line chemotherapy based on capecitabine (2 weeks on and 1 week off, total dose of 2,600 mg/day in days 1–14).

After 8 days of treatment, she visited the emergency room with progressive asthenia, grade 1 diarrhea, and grade 1 mucositis and was discharged after parenteral fluid support and intensive treatment with loperamide. Capecitabine was discontinued after 48 hours (cumulative dose 26 g) owing to rapidly increasing toxicity despite oral rehydration and a standard dose of loperamide. The main symptoms were diarrhea (grade 2), nausea (grade 2), odynophagia (grade 2), severe solid dysphagia, painful mucositis (grade 3), and progressive asthenia (grade 2) associated with low-grade fever. She was admitted to hospital immediately for close monitoring with intensive fluid and nutritional support, broad-spectrum antibiotics (piperacillin-tazobactam, vancomycin, and fluconazole), and pain relievers.

Both hematological toxicity (grade 4 neutropenia and grade 2 thrombocytopenia) and non-hematological toxicity (grade 1 palmar-plantar erythrodysesthesia, grade 2 diarrhea, and grade 3 mucositis) worsened rapidly. Her white blood cell count dropped, reaching a zero nadir at day +16 and remaining unchanged for over 6 days despite treatment with granulocyte colony-stimulating factor. The patient also developed anemia requiring erythrocyte and platelet transfusions. Her platelet nadir started to recover slowly at day +17.

Besides support with blood derivatives, she required third-step analgesia with strong opioids (morphine infusion pump) and intensive nutritional support with parenteral nutrition. The consequences of the severe mucositis and diarrhea resulted in low blood levels of potassium, calcium, phosphate, magnesium, and protein, with significant weight loss (up to 5 kg). In addition, the international normalized ratio was increased, with normal liver transaminases. Hand-foot syndrome progressed more slowly during hospitalization, with progressive, painful swelling and numbness on the palms and soles (up to grade 2), together with progressive alopecia that started 20 days after the withdrawal of capecitabine and lasted for more than 3 months. After 23 days in hospital, the patient was discharged with oral nutritional supplements that were necessary for over 2 months until she could tolerate a normal diet.

DPYD deficiency was suspected as a potential explanation for the life-threatening toxicity that developed after such a short interval of exposure to fluoropyrimidine, in the absence of liver or renal dysfunction and other potential drug interactions. The patient did not receive treatment with

fluoropyrimidines again. After two further chemotherapy lines, first cyclophosphamide+ zoledronic acid and later vinorelbine, the patient died due to disease progression.

A routine genetic *DPYD* test was carried out in our hospital because of the strong suspicion of *DPYD* deficiency. The three *DPYD* single-nucleotide polymorphisms (SNPs) were genotyped according to the recommendations of the Clinical Pharmacogenetics Implementation Consortium at the time.¹⁰ The SNPs were genotyped using real-time PCR and TaqMan probes. None of the three variants were detected. However, the presence of a *DPYD* deficit continued to be suspected. Therefore, after receiving written informed consent, we performed complete sequencing of the 23 *DPYD* exons. A total of 23 pairs of oligonucleotides (Table 1) were used to amplify and sequence *DPYD* exons. We identified two variants in *DPYD* exons, c.1601G>A (rs1801158, p.Ser534Asn, *DPYD**4) and a previously unreported splice site mutation at position 2242+1G>T, after the end of exon 19 (Figure 1). This variant was most probably affecting splicing as confirmed using Human Splicing Finder v3.1.¹¹

The effect of this second SNP on the donor splicing site was analyzed. RNA was isolated from peripheral blood mononuclear cells and processed to cDNA. A cDNA fragment from exon 18–20 was amplified using specific primers (forward [5'-TTAAAATCTGATGGCACACCTTG] and reverse [5'-TGCTTTTCAGATAAAGCAGGGCT]). PCR product sizes were estimated using electrophoresis. Sequencing of PCR products revealed skipping of exon 19 of *DPYD* in the patient's mRNA (Figure 2). *DPYD* generated a truncated protein of 795 amino acids lacking the correct sequence from 767 to the end (1025) (Figure 3). This region is considered essential for the functionality of the protein because it is part of the pyrimidine-binding domain (from 525 to 847).¹²

Due to the interest of this novel discovery and its potential clinical implications, genotyping of the mutation was later performed in the patient's offspring: one son, one daughter, and one granddaughter (a daughter descendant). For this purpose, a TaqMan probe was synthesized for 2242+1G>T. All individuals carried the 2242+1G>T mutation in heterozygosis. None of them presented the *DPYD** four allele.

DPYD phenotype assessment was performed by pretreatment measurement of plasma uracil (U) and dihydrouracil (UH2) in the descendants.¹³ Unfortunately, we were not able to analyze a sample from the original patient because at the time this analysis was performed, she was already deceased.

Two samples showed *DPYD* deficiency according to established criteria (uracil concentration >16 ng/mL and/or UH2/U ratio <6). The other sample showed values that

Table 1 List of primers used for *DPYD* exon sequencing

Exon number	Forward	Reverse	Fragment size
EXON 1	ACTTGCTCTCTGGCTGGAGCTT	AAACTTTCCCGCTCTCTCACTC	234
EXON 2	TTAGCCAGGTGTGGTAGCGTAC	TGCCTTACAATGTGTGGAGTG	410
EXON 3	TGAGACTTCTGTGACAGCTGTA	CCTCAAGGGAAGTCTCTCCAC	442
EXON 4	GGAGTGCCAAAGATGAAACACA	TGGATTTGCTAAGACAAGCTG	362
EXON 5	TCCTATGTGTCAAATACTCTGCT	TGGGTATCAACAGAGCACCA	444
EXON 6	AGGAGGCATGACTCTAGAAAGG	CCATTAAGAAATATTACAGGGCT	719
EXON 7	AGAATGTAGATGTCCTCATGCA	TGCATGACATTTGCTGTTAATC	331
EXON 8	AGCCCTTAATAGACATGTTCTT	TGAAGGCAGTCATTCTTCTGG	374
EXON 9	TGCTTACAGATGTTTTCTCT	ACAATGTGCTGCTGAGCTTG	324
EXON 10	TGGAAACTGCAAGATGCAA	AGCCCTTGAGTATTGACAAAG	312
EXON 11	TGGTGAAAGAAAAGCTGCAT	GTTCTTTTCAATACTTGCCACT	548
EXON 12	TGTGTGTAACTCCAATATTTCTG	TCAAGCATCCTCCCGCTT	621
EXON 13	TTCGGATGCTGTGTGAAGT	AATGTGTAATGATAGGCTTTGTCAA	443
EXON 14	GCTTTTCTTTGTCAAAGGAGAC	AGCTTCACATTGTGTGGGT	409
EXON 15	TAATTCCAAAGCCCCAAATG	TTTCTCATGGCAGCTCTTATTT	346
EXON 16	TCAACGGTGAAAGCCTATTG	AGCTTCCCTCATTTTCCACT	318
EXON 17	TTTGTCTTGCACGTCTCCAG	AGGATCTTGTGTTTCCAGATCA	437
EXON 18	TGAGAAAGTAAAGTTGTGGTAATT	GGGATCATAAAGGGCACAAA	423
EXON 19	TCCAGTGACGCTGTATCA	ACAGGACAGGAAATAAACCTCA	434
EXON 20	AGACGGCTACTGATCCATCA	TCTGAAATAGAAACCAAGGCTGA	375
EXON 21	CCCATTCTTCTTCTCTGAGC	ATGCATGCTTGCCAGTGT	423
EXON 22	TCTTTCAGAAGACAAACATCTAAGC	CAGAAAATGCTTTCTGCCGTA	402
EXON 23	ACGCTAAAATGGGGACATTG	ACATAAGACAACCTGGCAGTG	517
EXON SKIPPING	TTAAATCTGATGGCACACCTTG	TGCTTTTCAGATAAAGCAGGGCT

Figure 1 Sequence electropherogram of the 2242+1G>T variant. Blue, dCTP; green, dATP; black, dGTP; red, dTTP.

Abbreviations: dATP, deoxyadenosine triphosphate; dCTP, deoxycytidine triphosphate; dGTP, deoxyguanosine triphosphate; DPYD, dihydropyrimidine dehydrogenase; dTTP, deoxythymidine triphosphate.

were close to the limit but within the normal activity range. Phenotyping results are shown in Table 2.

A TaqMan probe was synthesized for genotyping of 2242+1G>T in a cohort of 487 anonymous DNA samples

from colorectal cancer patients (mainly Caucasians from Iberian ancestry). None of the samples analyzed, except that of the present case, carried this mutation, indicating that it is a rare variant in our setting.

Figure 2 Exon skipping sequence.

Notes: Left: Electrophoresis of amplified cDNA from peripheral blood mononuclear cells of a patient carrying the 2242+1G>T variant. Right, upper: Graphic representation of skipping of exon 19. Right, lower: Sequence electropherogram using the primer Ex18F. A double sequence is observed for 85 nucleotides corresponding to overlapping of exons 19 and 20.

Table 2 DPYD phenotyping results

UH2 concentration, ng/mL	U concentration, ng/mL	UH2/U concentration ratio	Activity ^a
89.32	13.47	6.6	Normal
85.16	24.13	3.5	Deficient
47.19	18.45	2.6	Deficient

Note: ^aCriteria for activity deficiency: uracil concentration >16 ng/mL and/or UH2/U ratio <6.

Abbreviations: UH2, dihydrouracil; U, uracil.

Discussion

The severe toxicity can be explained by the presence of the variant c.2242+1G>T, which generates shorter mRNA and protein, thus rendering a non-functional DPYD protein that lacks a sequence in the pyrimidine-binding domain (Figure 3). The SNP is just located in the first nucleotide after the end of exon 19. Other *DPYD* variants affecting donor splicing sites have also demonstrated skipping of the corresponding exon^{12,14} or generation of an in-frame insertion of small fragments causing severe and occasionally fatal adverse reactions to fluoropyrimidine.¹⁵

In this patient, a non-synonymous variant, c.1601G>A (rs1801158, p.Ser534Asn), was also observed. This variant defines the *DPYD** four allele and decreases protein activity

by 20%. However, although this allele has previously been related to the risk of fluoropyrimidine-induced toxicity,^{16,17} a recent meta-analysis did not find any significant association between c.1601G>A and severe fluoropyrimidine-induced toxicity.¹⁸ The DPYD deficiency observed in two out of three members of the family carrying the c.2242+1G>T mutation supports the effect of this variant on the fluoropyrimidine metabolism. The fact that none of them presented variant c.1601G>A further backs the theory that this new variant may be responsible for the descent in activity. As previously described, individuals carrying one functional and one non-functional allele of *DPYD* are likely to display a partial deficiency with $1.5 < \text{UH2/U} < 6$ ⁹. The third family member carrying this mutation showed a UH2/U ratio within the normal activity range, although close to the limit (6.6). This could be explained by factors not studied, such as copy number variants increasing the activity of the functional allele, or additional mutations in the other members.

The frequency of the *DPYD* variant c.2242+1G>T variant is lower than 0.002% in our setting, which suggests that it is a rare variant and its inclusion in our routine genotyping tests would not significantly increase their predictive value. Testing for this variant in other populations (since our sample is mainly integrated by Caucasian individuals of

Figure 3 Structures of wild-type *DPYD* and truncated *DPYD*.

Notes: The interpretation of mutation effect and the molecular modeling were performed by using Deep View Swiss-PDB viewer and Tasser. **(A)** Modeling of wild-type *DPYD*; **(B)** modeling of truncated *DPYD*.

Iberian ancestry) would be very interesting as it could help to investigate its possible origins. This is definitely a line of investigation to be pursued in future works.

Conclusion

We consider the newly described variant 2242+1G>T in *DPYD* to be the most probable cause of very severe toxicity following the first cycle of treatment with capecitabine in a patient with breast cancer. *DPYD* phenotyping in patient's offspring carrying the mutation showed decreased enzymatic activity, further supporting this conclusion. Whole *DPYD* sequencing is an interesting approach for the identification of causal variants in patients with suspected *DPYD* deficiency in whom routine *DPYD* tests yield negative results.

Ethics

Written informed consent was obtained from the three patient's family members that were tested for *DPYD* deficiency and from all patients in the colorectal cancer cohort that were tested for the presence of c.2242+1G>T. Written informed consent from the patient's next of kin was provided to have this case published since the patient was deceased at that time.

Acknowledgments

We would like to thank Luis Fernández Pacios at Universidad Politécnica de Madrid, for his support in modeling the *DPYD* 3D structure. The study was partially supported by the Ministry of Economy and Competitiveness grant PTA2013-8539-I (MIG), ISCIII-FIS grant PI12/00056, "Programa Miguel Servet II grant MSII13/00008" (LALF), and by "Consejería de Educación y Deporte de la Comunidad de Madrid" grant PEJ15/BIO/TL-0603 (CB) and PEJ16/MED/AI-1260

(LALF). All grants were cofunded by the European Regional Development Fund (ERDF [Fondo Europeo de Desarrollo Regional]) Funds from the European Commission "A way of making Europe." XGG was supported by a grant from Gregorio Marañón Health Research Institute.

Disclosure

The authors report no conflicts of interest in this work.

References

- Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. *Clin Colorectal Cancer*. 2006;6(4):288–296.
- Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. Deficiency dehydrogenase (DPD) in GI malignancies: experience of 4-years. *Pakistan J Med Sci*. 2007;23(6):832–839.
- Leicher LW, de Graaf JC, Coers W, Tascilar M, de Groot JW. Tolerability of capecitabine monotherapy in metastatic colorectal cancer: a real-world study. *Drugs R D*. 2017;17(1):117–124.
- Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. *Anticancer Drugs*. 2008;19(5):447–464.
- Rosmarin D, Palles C, Pagnamenta A, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at *DPYD* and a putative role for *ENOSF1* rather than *TYMS*. *Gut*. 2015;64(1):111–120.
- Milano G. Highlight on *DPYD* gene polymorphisms and treatment by capecitabine. *Scand J Clin Lab Invest Suppl*. 2016;245:S30–S33.
- Cortejoso L, García-González X, García MI, García-Alfonso P, Sanjurjo M, López-Fernández LA. Cost-effectiveness of screening for *DPYD* polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines. *Pharmacogenomics*. 2016;17(9):979–984.
- Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. *DPYD* IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. *Pharmacogenomics*. 2013;14(11):1255–1272.
- Thomas F, Hennebelle I, Delmas C, et al. Genotyping of a family with a novel deleterious *DPYD* mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. *Clin Pharmacol Ther*. 2016;99(2):235–242.

10. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. *Clin Pharmacol Ther*. 2013;94(6):640–645.
11. Desmet FO, Hamroun D, Lalande M, Collod-Bérout G, Claustres M, Bérout C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. *Nucleic Acids Res*. 2009;37(9):e67.
12. van Kuilenburg AB, Meijer J, Maurer D, et al. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. *Biochim Biophys Acta*. 2017;1863(3):721–730.
13. Etienne-Grimaldi MC, Boyer JC, Beroud C, et al. New advances in DPYD genotype and risk of severe toxicity under capecitabine. *PLoS One*. 2017;12(5):e0175998.
14. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. *Clin Cancer Res*. 2000;6(12):4705–4712.
15. Flegler M, Willomitzer J, Meinsma R, et al. Dihydropyrimidine dehydrogenase deficiency: metabolic disease or biochemical phenotype? *JIMD Rep*. 2017;37:49–54.
16. Loganayagam A, Arenas Hernandez M, Corrigan A, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. *Br J Cancer*. 2013;108(12):2505–2515.
17. Kleibl Z, Fidlerova J, Kleiblova P, et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. *Neoplasma*. 2009;56(4):303–316.
18. Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. *Lancet Oncol*. 2015;16(16):1639–1650.

Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>

Dovepress

a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.